HOME > ORGANIZATION
ORGANIZATION
- JPMA to Ponder Pricing System for New Modalities towards 2026 Reform: Chief
February 19, 2024
- Shipments Curbed or Suspended for 25.9% of Drugs in January: FPMAJ
February 19, 2024
- Payers, HCPs Hail First Step Taken for Generic Industry Revamp in FY2024 Reform
February 15, 2024
- Drug Supply Worsens for 3rd Month Running amid Flu Surge, Shipment Halts
February 13, 2024
- JGA Issues Written Reprimand to Sawai over GMP Issues
January 30, 2024
- JGA Chief Wary of “Full” Off-Year Revision in 2025, Urges Broader Exemptions If Plan Goes Forward
January 25, 2024
- Around 70 APIs Right Now Are Good Candidates for Rx-to-OTC Switches: JSMI Chair
January 24, 2024
- Japan Needs National Efforts to Boost Biosimilar Production: Kameda Chief Pharmacist
January 22, 2024
- Ishikawa Pharmacist Group Makes Direct Plea to Health Minister for Ad-Hoc Lifting of Shipment Curbs
January 19, 2024
- JPMA Calls for Setting Broad Spillover Exclusions in Market Expansion Re-Pricing
January 19, 2024
- 80-90% of Clinics in Northern Noto Not Functioning: JMA Official
January 12, 2024
- Wholesalers Ask for Prioritized Drug Supply for Disaster Areas; Emergency Dispensing Scheme Begins
January 11, 2024
- FPMAJ Stands Firmly Against Full Implementation of Off-Year Price Revision in FY2025
January 9, 2024
- Trade Groups, Academic Societies Urge Govt to Expand Coverage for CGP Testing
December 26, 2023
- Awareness Rate for Drug Lag, Loss at 17.6%, Up 5.2 Points from FY2022: JPMA Poll
December 22, 2023
- Reform Package Is “First Step” towards Global Standard, but More Work Remains: JPMA
December 22, 2023
- EFPIA Japan Names Novo’s Mejlvang as New Vice Chair
December 22, 2023
- Pharma Trade Groups Applaud FY2024 Drug Pricing Reform Outline
December 21, 2023
- JMA, JDA, JPA Call for Mitigation Measures for New LLP Coverage Rule
December 21, 2023
- Generic Use Rate Hits Record 82.2% in July-September: JGA
December 21, 2023
ページ
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…